Incidence of venous thromboembolism in hospitalized patients with COVID‐19

By S. Middeldorp, M. Coppens, T. V. van Haaps, M. Foppen, A. Vlaar, M. Müller, C. Bouman, L. Beenen, R. Kootte, J. Heijmans and 3 more. Journal of Thrombosis and Haemostasis, 2020

1,374 citations recorded by the source corpus.

Coronavirus disease 2019 (COVID‐19) can lead to systemic coagulation activation and thrombotic complications.

Subfields: Infectious Diseases, Internal Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/544058b37a22f877ce918410213c8ffa5ae06a57

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. Miguel A. Hern'an
2. R. Aftab
3. M. J. van der Laan

Citations in the corpus

• Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 (2020, background): “Time from symptom onset to blood sample, d — 6 (1-12)† 12 (8-17)”
• Coronavirus (COVID-19) (2020, background): “venous or arterial thromboembolic event(s) [76, 77], compared with 10–25% of hospitalized patients [77, 78].”
• Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. (2020, background): “Length of mechanical ventilatory support, median (IQR), d 11 (7-14) 13 (9-14) 9 (5-13)”
• Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis (2020, neutral): “Some studies have reported TE rates in the range of 20 (cid:1) 30% [4 (cid:1) 6] while others have reported rates as high as 40 (cid:1) 70% [7 (cid:1) 9].”